Clinical Trial Update: Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating gemcitabine hydrochloride with or without bevacizumab in patients undergoing surgery for pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Gemzar (gemcitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Status: WITHDRAWN